TEST CODE
|
NAME OF TEST
|
PREVIOUS REFERENCE VALUES
|
ACTUAL REFERENCE VALUES
|
|
816
|
METANEPHRINE
FRACTIONS , URINE
|
Normetanephrine
(3-methoxynoradrenaline): 162- 527 µg/24H
Metanephrine (3-methoxyadrenaline):
64- 302 µg/24H
|
Normetanephrine
(3-methoxynoradrenaline):
Less than 527 µg/24H
Metanephrine (3-methoxyadrenaline):
Less
than 302 µg/24H
|
|
5465
|
3-Methoxytyramine,
urine
|
94-399
µg/24H
|
Less
than 400 µg/24h
|
|
311
|
CATECHOLAMINES
- FRACTIONS, URINE
|
ADRENALINE :
0 - 1 year : 0 - 2.63 µg/24H 1 - 2 years : 0 - 3.57 µg/24H 2 - 4 years : 0 - 6.22 µg/24H 4 - 10 years: 0.18 - 10.37 µg/24H 10 - 15 years: 0.55 - 20 µg/24H 15 - 99 years: 0.01 - 20 µg/24H NORADRENALINE: 0 - 1 year : 0.01 - 9.48 µg/24H 1 - 2 years : 0.95 - 16 µg/24H 2 - 4 years : 3.85 - 27.48 µg/24H 4 - 7 years : 7.55 - 42.75 µg/24H 7 - 10 years: 12.36 - 61.72 µg/24H 10 - 15 years: 14.30 - 75 µg/24H 15 - 99 years: 14.30 - 75 µg/24H DOPAMINE: 0 - 1 year : 0.01 - 85 µg/24H 1 - 2 years : 10 - 140 µg/24H 2 - 4 years : 40 - 260 µg/24H 4 - 15 years: 65 - 400 µg/24H 15 - 99 years: 65 - 400 µg/24H |
Adrenaline:
Less than 20 µg/24H
Noradrenaline: Less than 80 µg/24H Dopamine: Less than 400 |
|
312
|
CATECHOLAMINES
- FRACTIONS, PLASMA
|
Supine
position:
ADRENALINE : 30 - 60 pg/mL NORADRENALINE : 40 - 400 pg/mL DOPAMINE : 10 - 150 pg/mL Orthostatic position: ADRENALINE : 30 - 60 pg/mL NORADRENALINE : < 600 pg/mL DOPAMINE : 10 - 150 pg/mL |
Noradrenaline:
Less than 420 pg/mL Adrenaline: Less than 84 pg/mL
Dopamina: Less than 85pg/mL |
|
105
|
VANYLMANDELIC
ACID (VMA), URINE
|
Children
1-4 years: Less than 3.1 mg/24H
4-10 years: Less than 4.3 mg/24H Adults : 2 - 10 mg/24H |
1.8-6.7
mg/24h
|
|
838
|
5-HYDROXYINDOLACETIC ACID, URINE
|
2 - 9 mg/24H
* It is recommended to stop medications, and foods such as bananas, pineapple, eggplant, nuts, watermelon, tomato, Plum, blueberry 72 hours before sample collection. |
0.7-8.2
mg/24h
|
|
266
|
HOMOVANILIC
ACID, URINE
|
Children:
Less than 5 mg/24H
Adults : Less than 10 mg/24H |
Less
than 6.2 mg/24h
|
|
2416
|
LAMOTRIGIN
, SERUM
|
Therapeutic
levels: 2.6 -15.4 µg/mL
|
3-14 mg/L
|
|
347
|
ETHOSUXIMIDE
(ZARONTIN), SERUM
|
Therapeutic
level (childs): 40 - 80 µg/mL
(Adults): 40 - 100 µg/mL Toxic level : > 100 µg/mL |
30-100 mg/L
|
|
403
|
PRIMIDONE,
SERUM
|
Therapeutic
level: 5 - 12 µg/Ml Toxic level: Greater than 15 µg/mL
|
4-12 mg/L
|
|
849
|
HYPURIC
ACID, URINE
|
Not
exposed: Less than 0.9 g/g creatinine
Exposed: Less than 1.6 g/g creatinine |
B.L.V.
(Biological Limited Value)
I.N.S.H.T.
Not exposed: Less than 0.97 g/g creatinine Exposed: Less than 1.6 g/g creatinine |
|
396
|
LEAD
(PB), WHOLE BLOOD
|
Unexposed
workers: Less than 5 µg/dL (*)
B.L.V: Up to 70 µg/dL (**) B.L.V: Biological limit value Bibliography * National Institute of Occupational Safety and Health (NIOSH), 2015 ** Instituto Nacional de Seguridad e Higiene en el Trabajo (INSHT), 2016 |
Not
exposed: Less than 10 µg/dL
IBE: 30 µg/dL
B.L.V.:
70 µg/dL
|
|
882
|
LEAD
(PB), URINE
|
Not
exposed: Less than 40 µg/g creatinine
B.E.I.: Less than 150 µg/g creatinine |
Not
Exposed: Less than 10 µg/g creatinine
B.E.I.: 150 µg/g creatinine |
|
2049
|
NICKEL,
SERUM
|
No
exposed: Less than 2 µg/L
B.E.I (Exposure Index): 10 µg/L |
Not
exposed: Less than 2 µg/L
|
|
299
|
CADIUM,
WHOLE BLOOD
|
Not
exposed : Less than 5 µg/L
B.E.I. : Less than 10 µg/L |
Not
exposed : Less than. a 1 µg/L
B.E.I. : Less than 5 µg/L B.L.V. (F.T.): 5 µg/L |
|
3066
|
CADIUM,
URINE
|
N.E.: Less than 0.5 µg/g creatinine
B.E.I.: 5.0 µg/g creatinine. |
Not Exposed: Less than 5 µg/g creatinine
|
|
421
|
ZINC,
SERUM
|
Less
than 6 months: 26 - 141 µg/dL
6 - 12 months: 29 - 131 µg/dL 12 - 2 years: 31 - 120 µg/dL 2 - 4 years: 29 - 115 µg/dL 4 - 6 years: 48 - 119 µg/dL 6 – 10 years: 48 - 129 µg/dL 10 - 14 years: 25 - 148 µg/dL 14 - 18 years: 46 - 130 µg/dL Greather than 18 years: 60 - 150 µg/dL |
60
- 150 µg/dL
|
|
6007
|
MANGANESE,
WHOLE BLOOD
|
Not
exposed: Less than 10 µg/L
B.E.I. (EWD): For manganese, elemental and inorganic compounds: 20 µg/L |
Not
exposed: Less than 6-12 µg/L
B.E.I. (EWD): For manganese. elemental and inorganic compounds: 20 µg/L |
|
330
|
CHROMIUM,
SERUM
|
No
exposed: Less than 2.2 µg/L
|
Less
than 2.2 µg/L
|
|
983
|
Clobazam,
norclobazam and ratio, serum
|
.
Therapeutic Area:
Clobazam : 30 - 300 µg/L Norclobazam: 300 - 3000 µg/L Norclobazam/Clobazam Ratio: Less than 10 . Toxic Concentration: Clobazam : Higher to 3000 µg/L Norclobazam : Higher to 12000 µg/L . Comment: The Norclobazam/Clobazam ratio may be useful for information on the drug metabolizing capacity and improve dose adjustment. Very high ratios (> 25) indicate that the patient is a poor metabolizer of CYP2C19 (if not taking drugs that induce CYP3A or CYP2C19 inhibitors). Note: The presence of Norclobazam must be evaluated only if no Clonazepam therapy because it interferes with the analytical determination. *Ther Drug Monit. 2013 Feb;35(1):30-47. doi: 10.1097/FTD.0b013e31827ada88. Clobazam therapeutic drug monitoring: a comprehensive review of the literature with proposals to improve future studies. De Leon J, Spina E, Diaz FJ. |
Clobazam :
30 - 300 µg/L
Norclobazam: 300 - 3000 µg/L Norclobazam/Clobazam Ratio: Less than 10 |
|
530
|
CLONAZEPAM
(RIVOTRIL), SERUM
|
Therapeutic
level: 10 - 80 ng/mL
Toxic level : Greater than 100 ng/mL Note: The presence of Norclobazam be assessed only in the case of therapy without Clonazepam. Clobazam and Clonazepam therapy can interfere with both determinations. NORCLOBAZAM Orientative Therapeutic level: 1000 - 3000 ng/mL |
10-80
µg/L
|
|
745
|
DIAZEPAM
(VALIUM), SERUM
|
TERAPEUTIC
LEVEL: 200 - 2000 µg/L
TOXIC LEVEL: Superior a 3000 µg/L * M.Schulz, A. Schmoldt A. (2003) Therapeutic and Toxid Blood Concentrations of More than 800 Drugs and other xenobiotics. Pharmazie 58 (7): 447-74. |
125-250
µg/L
|
|
1737
|
BROMAZEPAM,
SERUM
|
Therapeutic
level: 80 - 150 ng/mL
|
80-170
µg/L
|
|
281
|
AMITRIPTYLINE
/ NORTRIPTYLINE, SERUM
|
THERAPEUTIC
LEVEL: 50 - 300 ng/mL
TOXIC LEVEL : Greater than 500 ng/mL * NOTE: Amitritilyne metabolizes partially to nortriptyline and both of them are of concern in therapeutic values. The therapeutic values are refer to addition of both metabolites. |
80-200
µg/L
|
|
2890
|
CLOZAPINE,
SERUM
|
50
- 700 ng/mL
|
300-800
µg/L
|
|
365
|
IMIPRAMINE
/ DESIPRAMINE, SERUM
|
Therapeutic
level: 30 - 300 µg/L
Toxic level : Greater than 500 µg/L *Imipramine metabolizes partially to desipramine and both of them are of concern in therapeutic values. The therapeutic values are refer to addition of both metabolites. * F.E.Krapf, W.P. Bieger, F.W. Tiller: LaborDatenBuch (1995) Urban & Schwarzenberg, München. |
175-300
µg/L
|
|
799
|
CLOMIPRAMINE
/ DISMETHYLCLOMIPRAMINE , SERUM
|
CLOMIPRAMINE:
Therapeutic level: 90 - 250 ng/mL Toxic level : > 400 ng/mL DISMETHILCLOMIPRAMINE: Therapeutic level: 150 - 300 ng/mL * M.Schulz, A. Schmoldt, Pharmazie (2003) 58(7), 447. |
CLOMIPRAMINE:
20 - 250 µg/L DISMETHILCLOMIPRAMINE: 20 - 250 µg/L |
|
363
|
17 alpha hydroxyprogesterone, serum
|
Childs (blood cord) : 9.0 -50.0 ng/mL
(Prematures) : 0.26- 5.68 ng/mL (1 - 5 days) : 0.82- 4.20 ng/mL (5 - 30 days): 0.1 -16.8 ng/mL (30- 60 days): 1.9 - 9.8 ng/mL (60- 90 days): 0.1 - 4.0 ng/mL (Prepuberty phase): 0.10- 0.90 ng/mL (Puberal phase) : 0.30- 1.55 ng/mL Male : 0.59 - 3.44 ng/mL Female : Follicular phase: 0.11 - 1.08 ng/mL Luteinic phase : 0.95 - 5.0 ng/mL Pregnant 1er Trim.: 2.50 - 9.78 ng/mL 2nd Trimonthter: 3.40 - 8.50 ng/mL 3rd Trimonthter: 4.53 - 18.86 ng/mL |
Childs (blood cord) : 9.0 -50.0 ng/mL
Prematures : 0.26- 5.68 ng/mL Prepuberty phase: Boys: 11 years: 0.03-0.90 ng/ml 11-13 years: 0.05- 1.15 ng/ml 13-15 years: 0.10-1.39 ng/ml 15-17 years: 0.29-1.80 ng/ml 17-20 years: 0.24-1.75 ng/ml Girls: 11 years: 0.03-0.82 ng/ml 11-13 years: 0.11-0.98 ng/ml 13-15 years: 0.11-1.55 ng/ml 15-17 years: 0.18-2.30 ng/ml 17-20 years: 0.20-2.67 ng/ml Male : 0.59 - 3.44 ng/mL Women: Follicular phase : 0.11 - 1.08 ng/mL Luteinic phase : 0.95 - 5.0 ng/mL Pregnant 1er Trimester: 2.50 - 9.78 ng/mL 2nd Trimester: 3.40 - 8.50 ng/mL 3rd Trimester: 4.53 - 18.86 ng/mL |
|
284
|
CYCLIC AMP (C-AMP), URINE
|
1 - 11.5 µmol/24H
|
2.66-10.0 µmol/24h
|
|
4219
|
ANDROSTENEDIONE - DELTA-4 - RIA, SERUM
|
CHILDREN: 0.1 - 0.9 ng/mL
MEN: 0.5 - 4.8 ng/mL WOMEN: Follicular phase: 0.9 - 3 ng/mL Ovulatory phase: 1.9 - 4.7 ng/mL Luteinic phase: 1.1 - 4.2 ng/mL Postmenopausal: 0.3 -3.7 ng/mL Poliquistic ovary syndrome: 2.2 - 6.5 ng/mL |
CHILDREN: 0.1 - 0.9 ng/mL
MEN: 0.5 - 4.8 ng/mL WOMEN: 0.5 - 4.7 ng/mL Follicular phase: 0.9 - 3 ng/mL Ovulatory phase: 1.9 - 4.7 ng/mL Luteinic phase: 1.1 - 4.2 ng/mL Postmenopausal: 0.3 -3.7 ng/mL Poliquistic ovary syndrome: 2.2 - 6.5 ng/mL |
|
327
|
CORTISOL - FREE, URINE
|
30
- 197 nmol/24 H
|
10.9-71.4
µg/24 h
|
|
334
|
11-Desoxycortisol, serum
|
Without
stimulus : Less than 7.2 ng/mL
Post metopirone: 72-255 ng/mL * Realised research by laboratory. |
Without stimulus : Less than 7.2 ng/mL
Post metopirone: Greater than 193.95 ng/mL |
|
332
|
DEHYDROEPIANDROSTENEDIONE (DHEA), SERUM
|
Children
: 0.3 - 5.4 ng/mL
Males : 1.4 - 12.5 ng/mL Females : 0.8 - 10.5 ng/mL |
Boys:
6-9 years: 0.13-1.87 ng/ml 10-11 years: 0.31 - 2.05 ng/ml 12-14 years: 0.83 - 2.58 ng/ml Girls: 6-9 years: 0.18-1.89 ng/ml 10-11 years: 1.12-2.24 ng/ml 12-14 years: 0.98 - 3.60 ng/ml Men (16-79 years): 1.4-12.5 ng/ml Women (22 - 80 years): 0.8-10.5 ng/ml |
|
228
|
RENIN (ACTIVITY), PLASMA
|
Upright:
1.9 - 6 ng/mL/H
Supine : 0.5 - 1.9 ng/mL/H |
Adults:
Orthostatic position: 0.60 - 4.18 ng / mL / h Supine position: 0.32 - 1.84 ng / mL / h |
|
434
|
T3 REVERSE, SERUM
|
ADULTS:
0.1 - 0.35 ng/mL
|
Boys: Blood cord(>37 weeks): 1.30-3.00 ng/ml 1 day: 0.83-1.94 ng/ml 2 days: 1.07-2.09 ng/ml 3 days: 1.02-1.66 ng/ml Adults: 0.09-0.35 ng/mL |
|
418
|
VITAMINA 1,25 OH
|
Adults:
18 - 78 pg/mL
14
to 17 years: 19 - 83 pg/mL
10 to 13 years: 30 - 83 pg/mL 1 to 9 years: 31 - 87 pg/mL |
19.6
- 54.3 pg/ml
|
Tuesday, January 10, 2017
We inform you as of tomorrow 11th January 2017, the reference values of the following tests have been modified.
Subscribe to:
Post Comments (Atom)
No comments:
Post a Comment